JIMT-1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
JIMT-1 is a breast cancer cell line established from a 62-year-old woman’s pleural effusion with ductal breast cancer in 2003. These cells carry an amplified HER-2 oncogene, making them insensitive to HER-2-inhibiting drugs. JIMT-1 cells lack estrogen and progesterone receptors and overexpress HER-2 mRNA and protein. JIMT-1 cells are of epithelial progenitor cell origin, confirmed by positive immunohistochemical staining for cytokeratins 5/14 and 8/18. They grow as an adherent monolayer and can therefore be culture in DMEM with 10% FBS.
Why choose JIMT-1 from AcceGen?
JIMT-1 cell line from AcceGen possesses several key features. Firstly, it undergoes routine authentication through STR profiling, ensuring the consistency and reliability of its genetic identity. Secondly, the cells are maintained under sterile conditions and regularly tested to confirm the absence of bacterial, fungal, and mycoplasma contamination. This ensures the integrity of experiments and prevents potential cross-contamination. Lastly, the cell line is handled professionally, with careful cryopreservation techniques employed to maintain high viability. These features contribute to the quality and reliability of JIMT-1 cells for use in various research applications.
| Product Code | JIMT1; JIMT |
| Species | Human |
| Cat.No | ABC-TC504S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Breast |
| Disease | Breast Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The JIMT-1 breast cancer cell line offers valuable applications in cancer research and drug development. It can form xenograft tumors in mice, allowing researchers to study the effectiveness of drugs or inhibitors both in vitro and in vivo. For instance, JIMT-1 cells have been extensively used to test HER-2-targeting drugs and small molecule tyrosine kinase inhibitors aimed at inhibiting the HER-2 pathway. Additionally, JIMT-1 cells can be utilized for genomic screening to identify key genes involved in cell proliferation and tumor growth. These applications make JIMT-1 a valuable tool for understanding breast cancer biology, exploring drug resistance mechanisms, and developing targeted therapies.
JIMT-1 cell line doubling time is 30-40h, and it is recommended to change medium every 2-3 days.
JIMT-1 cells overexpress HER-2 mRNA and are insensitive to drugs that inhibit HER-2 (such as trastuzumab). JIMT-1 cells have an amplified HER-2 oncogene, which showed no identifiable mutations in its coding sequence.
The cell line lacks expression of hormone receptors (estrogen receptors and progesterone receptors) and is phenotypically of epithelial progenitor cell origin.
The recommended cell density for JIMT-1 cells before passage is 1-2 × 10^5 cells/mL. We recommend to use a T-25 setup at a dilution of 1:5-1:10 (our cell count is approximately 1-2M/vial).
